Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

BACKGROUND: Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune checkpoint inhibitors. While the molecular heterogeneity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Loupakis, Fotios, Maddalena, Giulia, Depetris, Ilaria, Murgioni, Sabina, Bergamo, Francesca, Dei Tos, Angelo Paolo, Rugge, Massimo, Munari, Giada, Nguyen, Andrew, Szeto, Christopher, Zagonel, Vittorina, Lonardi, Sara, Fassan, Matteo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842181/
https://ncbi.nlm.nih.gov/pubmed/31703605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0788-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados